
Vir Biotechnology, Inc.: updates and filings
Price
$8.87
November 19, 2026Market cap $1.5B
What Ploutos Investor adds for Vir Biotechnology
Part of Ploutos Investor, €9.99 a month
- The full history: 9 fiscal years, from 2017
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 25% since Nov 4, 2026, when the 10-Q these figures come from was filed ($11.77 then, $8.87 on Nov 19, 2026). The figures date from before that move.10-Q
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Nov 4, 2026next Feb 5, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
November 2026
October 2026
August 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Material agreement entered, other material eventsForm8-K
- Nov 12, 2026Shelf registration for future offeringsFormS-3ASR
- Nov 10, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Nov 9, 2026Regulation FD disclosure, other material eventsForm8-K
- Nov 6, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Nov 4, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Nov 4, 2026Results of operationsForm8-K
- Oct 28, 2026Officer or director changeForm8-K
- Oct 27, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Oct 14, 2026Unregistered sale of shares, other material eventsForm8-K
- Oct 8, 2026Other material eventsForm8-K
- Oct 1, 2026Officer or director change, Regulation FD disclosureForm8-K
- Aug 7, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 5, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 5, 2026Results of operationsForm8-K
- Jul 31, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jul 24, 2026Officer or director changeForm8-K
- Jun 10, 2026Officer or director changeForm8-K
- May 28, 2026Officer or director change, shareholder voteForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 7, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 6, 2026Results of operationsForm8-K
- Apr 29, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 16, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 16, 2026Additional annual meeting materialFormDEFA14A
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | 8-K | Material agreement entered, other material events | Document |
| Nov 12, 2026 | S-3ASR | Shelf registration for future offerings | Document |
| Nov 10, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Nov 9, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Nov 6, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Nov 4, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Nov 4, 2026 | 8-K | Results of operations | Document |
| Oct 28, 2026 | 8-K | Officer or director change | Document |
| Oct 27, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Oct 14, 2026 | 8-K | Unregistered sale of shares, other material events | Document |
| Oct 8, 2026 | 8-K | Other material events | Document |
| Oct 1, 2026 | 8-K | Officer or director change, Regulation FD disclosure | Document |
| Aug 7, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 5, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 5, 2026 | 8-K | Results of operations | Document |
| Jul 31, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jul 24, 2026 | 8-K | Officer or director change | Document |
| Jun 10, 2026 | 8-K | Officer or director change | Document |
| May 28, 2026 | 8-K | Officer or director change, shareholder vote | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 7, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 6, 2026 | 8-K | Results of operations | Document |
| Apr 29, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 16, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 16, 2026 | DEFA14A | Additional annual meeting material | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jun 29, 2018.
The full analysis
What do Vir Biotechnology's filings show?
The filings are where every one of Vir Biotechnology's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.